Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity

Molecular Cell

Volumn 23, Issue 2, 2006, Pages 251-263

  Wallace, Maura ^a   Worrall, Erin ^a   Pettersson, Susanne ^a   Hupp, Ted R ^a   Ball, Kathryn L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

CELLCYCLE; PROTEINS

Indexed keywords

PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

AMINO TERMINAL SEQUENCE; ARTICLE; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING MOTIF; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME MECHANISM; ENZYME REGULATION; HOMEOBOX; HUMAN; HUMAN CELL; HYDROPHOBICITY; MUTAGENESIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION;

AMINO ACID SEQUENCE; CELLS, CULTURED; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 33745949757     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2006.05.029     Document Type: Article

References (27)

1. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., Bond G.L., Levine A.J., and Bargonetti J. A chromatin associated and transcriptionally inactive p53-MDM2 complex occurs in MDM2 SNP 309 homozygous cells. J. Biol. Chem. 280 (2005) 26776-26787
2. Bottger V., Bottger A., Howard S.F., Picksley S.M., Chene P., Garcia-Echeverria C., Hochkeppel H.K., and Lane D.P. Identification of novel mdm2 binding peptides by phage display. Oncogene 13 (1996) 2141-2147
3. Bottger A., Bottger V., Sparks A., Liu W.L., Howard S.F., and Lane D.P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7 (1997) 860-869
4. Brooks C.L., and Gu W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21 (2006) 307-315
5. Burch L.R., Midgley C.A., Currie R.A., Lane D.P., and Hupp T.R. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett. 472 (2000) 93-98
6. Dornan D., and Hupp T.R. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep. 2 (2001) 139-144
7. Esser C., Scheffner M., and Hohfeld J. The chaperone associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem. 280 (2005) 27443-27448
8. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
9. Hsieh J.K., Chan F.S., O'Connor D.J., Mittnacht S., Zhong S., and Lu X. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3 (1999) 181-193
10. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., and Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (1996) 948-953
11. Laney J.D., and Hochstrasser M. Substrate targeting in the ubiquitin system. Cell 97 (1999) 427-430
12. Lin J., Chen J., Elenbaas B., and Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8 (1994) 1235-1246
13. Liu W.L., Midgley C., Stephen C., Saville M., and Lane D.P. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. J. Mol. Biol. 313 (2001) 711-731
14. Maki C.G., and Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17 (1997) 355-363
15. Meulmeester E., Frenk R., Stad R., de Graaf P., Marine J.C., Vousden K.H., and Jochemsen A.G. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol. 23 (2003) 4929-4938
16. Michael D., and Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13 (2003) 49-58
17. Milne D., Kampanis P., Nicol S., Dias S., Campbell D.G., Fuller-Pace F., and Meek D. A novel site of AKT-mediated phosphorylation in the human MDM2 onco-protein. FEBS Lett. 577 (2004) 270-276
18. Patton J.T., Mayo L.D., Singhi A.D., Gudkov A.V., Stark G.R., and Jackson M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 66 (2006) 3169-3176
19. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70 (2001) 503-533
20. Rohaly G., Chemnitz J., Dehde S., Nunez A.M., Heukeshoven J., Deppert W., and Dornreiter I. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122 (2005) 21-32
21. Schon O., Friedler A., Freund S., and Fersht A.R. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J. Mol. Biol. 336 (2004) 197-202
22. Shimizu H., and Hupp T.R. Intrasteric regulation of MDM2. Trends Biochem. Sci. 28 (2003) 346-349
23. Shimizu H., Burch L.R., Smith A.J., Dornan D., Wallace M., Ball K.L., and Hupp T.R. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277 (2002) 28446-28458
24. Shimizu H., Saliba D., Wallace M., Finlan L., Langridge-Smith P., and Hupp T. Destabilizing mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem. J. 397 (2006) 355-367 10.1042/BJ20051521 Published online March 31, 2006
25. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
26. Xirodimas D., Saville M.K., Edling C., Lane D.P., and Lain S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 20 (2001) 4972-4983
27. Yu G.W., Rudiger S., Veprintsev D., Freund S., Fernandez-Fernandez M.R., and Fersht A.R. The central region of HDM2 provides a second binding site for p53. Proc. Natl. Acad. Sci. USA 103 (2006) 1227-1232